Novel adopted immunotherapy for mixed chimerism after unrelated cord blood transplantation in Omenn syndrome

European Journal of Haematology

Volumn 75, Issue 5, 2005, Pages 441-444

  Tomizawa, Daisuke ^a   Aoki, Yuki ^a   Nagasawa, Masayuki ^a   Morio, Tomohiro ^a,b   Kajiwara, Michiko ^b   Sekine, Teruaki ^c   Shimizu, Norio ^a,b   Kato, Masahiko ^d   Yachie, Akihiro ^e   Mizutani, Shuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY HOSPITAL   (Japan)

^c Lymphotec Inc   (Japan)

^d Gumna Children S Medical Center   (Japan)

^e KANAZAWA UNIVERSITY   (Japan)

Author keywords

Cord blood transplantation; Donor lymphocyte infusion; Omenn syndrome

Indexed keywords

CYCLOSPORIN A; METHYLPREDNISOLONE; PREDNISOLONE;

ADOPTIVE IMMUNOTHERAPY; ANAMNESIS; ARTICLE; CASE REPORT; CHIMERA; CORD BLOOD STEM CELL TRANSPLANTATION; DONOR; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LABORATORY TEST; LYMPHOCYTE TRANSFUSION; MALE; OMENN SYNDROME; PRIORITY JOURNAL; T LYMPHOCYTE;

CD4-POSITIVE T-LYMPHOCYTES; CORD BLOOD STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INFANT; LYMPHOCYTE TRANSFUSION; MALE; SEVERE COMBINED IMMUNODEFICIENCY; SYNDROME; TRANSPLANTATION CHIMERA; TREATMENT OUTCOME;

EID: 26844461375     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00535.x     Document Type: Article

References (18)

1. OMENN GS. Familial reticuloendotheliosis with eosinophilia. N Engl J Med 1965;273:427-432.
2. OCHS HD, DAVIS SD, MICKELSON E, LERNER KG, WEDGWOOD RJ. Combined immunodeficiency and reticuloendotheliosis with eosinophilia. J Pediatr 1974;85:463-465.
3. VILLA A, SANTAGATA S, BOZZI F, et al. Partial V(D)J recombination activity leads to Omenn syndrome. Cell 1998;93:885-896.
4. ALEMAN K, NOORDZIJ JG, DE GROOT R, van DONGEN JJ, HARTWIG NG. Reviewing Omenn syndrome. Eur J Pediatr 2001;160:718-725.
5. GOMEZ L, LE DEIST F, BLANCHE S, CAVAZZANA-CALVO M, GRISCELLI C, FISCHER A. Treatment of Omenn syndrome by bone marrow transplantation. J Pediatr 1995;127:76-81.
6. LOECHELT BJ, SHAPIRO RS, JYONOUCHI H, FILIPOVICH AH. Mismatched bone marrow transplantation for Omenn syndrome: a variant of severe combined immunodeficiency. Bone Marrow Transplant 1995;16:381-385.
7. BRÜCKMANN C, LINDNER W, ROOS R, PERMANETTER W, HAAS RJ, HAWORTH SG, BELOHRADSKY BH. Severe pulmonary vascular occlusive disease following bone marrow transplantation in Omenn syndrome. Eur J Pediatr 1991;150:242-245.
8. ANTOINE C, MÜLLER S, CANT A, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 2003;361:553-560.
9. AMROLIA P, GASPAR HB, HASSAN A, et al. Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood 2000;96:1239-1246.
10. ROSSI G, ZECCA M, GIORGIANI G, BONETTI F, DE STEFANO P, LOCATELLI F. Non-myeloablative stem cell transplantation for severe combined immunodeficiency - Omenn syndrome. Br J Haematol 2004;125:406-407.
11. CHILDS R, CLAVE E, CONTENTIN N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999;94:3234-3241.
12. SOIFFER RJ, GONIN R, MURRAY C, et al. Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation. Blood 1993;82:2216.
13. NIMER SD, GIORGI J, GAJEWSKI JL, et al. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial. Transplantation 1994;57:82.
14. ALYEA EP, SOIFFER RJ, CANNING C, NEUBERG D, SCHLOSSMAN R, PICKETT C, COLLINS H, WANG Y, ANDERSON KC, RITZ J. Toxicity and efficacy of defined dose of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998;91:3671-3680.
15. WADA T, TOMA T, OKAMOTO H, et al. Oligoclonal expansion of T lymphocytes with multiple second-site mutations leads to Omenn syndrome in a patient with RAG1-deficient severe combined immunodeficiency. Blood 2005 (in press).
16. SEKINE T, SHIRAIWA H, YAMAZAKI T, TOBISU K, KAKIZOE T. A feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy of cancer patients. Biomed Pharmacother 1993;47:73-78.
17. NUMAZAKI K, IKEHATA M, YANAI S, UMETSU M, MOTOYA H, CHIBA S, SEKINE T. Adoptive immunotherapy for interstitial pneumonia associated with cytomegalovirus infection. Clin Infect Dis 1997;25:1246-1247.
18. TAKAYAMA T, SEKINE T, MAKUUCHI M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet 2000;356:802-827.